
David I Quinn Mbbs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3070957/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 2017, 376, 1015-1026.	13.9	2,677
2	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, The, 2017, 389, 67-76.	6.3	1,728
3	Isolation of exosomes from whole blood by integrating acoustics and microfluidics. Proceedings of the United States of America, 2017, 114, 10584-10589.	3.3	633
4	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	13.7	572
5	Intermittent versus Continuous Androgen Deprivation in Prostate Cancer. New England Journal of Medicine, 2013, 368, 1314-1325.	13.9	482
6	Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3410-3415.	3.3	425
7	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. New England Journal of Medicine, 2021, 385, 683-694.	13.9	394
8	Prolonged Fasting Reduces IGF-1/PKA to Promote Hematopoietic-Stem-Cell-Based Regeneration and Reverse Immunosuppression. Cell Stem Cell, 2014, 14, 810-823.	5.2	369
9	A Preoperative Nomogram Identifying Decreased Risk of Positive Pelvic Lymph Nodes in Patients With Prostate Cancer. Journal of Urology, 2003, 170, 1798-1803.	0.2	365
10	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1652-1659.	0.8	332
11	Fasting and cancer treatment in humans: A case series report. Aging, 2009, 1, 988-1007.	1.4	305
12	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncology, The, 2015, 16, 426-435.	5.1	272
13	Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 1136-1142.	0.8	268
14	A Universal Standard for the Validation of Blood Pressure Measuring Devices. Hypertension, 2018, 71, 368-374.	1.3	257
15	Randomized Controlled Trial of Collaborative Care Management of Depression Among Low-Income Patients With Cancer. Journal of Clinical Oncology, 2008, 26, 4488-4496.	0.8	239
16	Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nature Medicine, 2010, 16, 324-328.	15.2	211
17	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations. Cancer Discovery, 2018, 8, 812-821.	7.7	206
18	International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy. Journal of Clinical Oncology, 2002, 20, 3206-3212.	0.8	203

#	Article	IF	CITATIONS
19	Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma. Journal of Clinical Oncology, 2012, 30, 2509-2515.	0.8	199
20	Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2010, 16, 3028-3034.	3.2	187
21	Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Research, 2003, 63, 4196-203.	0.4	185
22	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
23	Molecular markers of prostate cancer outcome. European Journal of Cancer, 2005, 41, 858-887.	1.3	173
24	Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2012, 30, 507-512.	0.8	168
25	Oscillometric blood pressure: a review for clinicians. Journal of the American Society of Hypertension, 2014, 8, 930-938.	2.3	159
26	Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer, 2016, 16, 360.	1.1	153
27	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma—Neoadjuvant and Adjuvant Settings. European Urology, 2013, 63, 58-66.	0.9	151
28	Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 893-900.	5.1	139
29	Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. Journal of Urology, 2015, 194, 378-385.	0.2	137
30	A universal standard for the validation of blood pressure measuring devices. Journal of Hypertension, 2018, 36, 472-478.	0.3	135
31	EphB4 Expression and Biological Significance in Prostate Cancer. Cancer Research, 2005, 65, 4623-4632.	0.4	129
32	Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer. Clinical Nuclear Medicine, 2012, 37, 637-643.	0.7	125
33	Human immunodeficiency virus-related primary central nervous system lymphoma. Cancer, 2004, 100, 2627-2636.	2.0	123
34	Expression and Significance of Vascular Endothelial Growth Factor Receptor 2 in Bladder Cancer. Journal of Urology, 2006, 175, 1245-1252.	0.2	122
35	Formation and size distribution of self-assembled vesicles. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2910-2915.	3.3	113
36	Baseline ¹⁸ F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2013, 54, 1195-1201.	2.8	110

#	Article	IF	CITATIONS
37	Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317. Journal of Clinical Oncology, 2009, 27, 5788-5793.	0.8	108
38	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer, 2014, 120, 2684-2693.	2.0	105
39	Validation Study of the Accuracy of a Postoperative Nomogram for Recurrence After Radical Prostatectomy for Localized Prostate Cancer. Journal of Clinical Oncology, 2002, 20, 951-956.	0.8	104
40	Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene, 2003, 22, 6005-6012.	2.6	103
41	Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2020, 38, 1797-1806.	0.8	102
42	Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncology, The, 2012, 13, 1055-1062.	5.1	101
43	Factors influencing postâ€recurrence survival in bladder cancer following radical cystectomy. BJU International, 2012, 109, 846-854.	1.3	101
44	Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. European Journal of Cancer, 2014, 50, 3145-3152.	1.3	99
45	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology, 2018, 36, 1579-1587.	0.8	97
46	Fabrication of conductive gelatin methacrylate–polyaniline hydrogels. Acta Biomaterialia, 2016, 33, 122-130.	4.1	90
47	Zinc-alpha2-glycoprotein Expression as a Predictor of Metastatic Prostate Cancer Following Radical Prostatectomy. Journal of the National Cancer Institute, 2006, 98, 1420-1424.	3.0	89
48	Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial. Urology, 2010, 76, 923-926.	0.5	89
49	Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy. Cancer, 2003, 97, 1884-1893.	2.0	86
50	The AKT Inhibitor Perifosine in Biochemically Recurrent Prostate Cancer: A Phase II California/Pittsburgh Cancer Consortium Trial. Clinical Genitourinary Cancer, 2007, 5, 433-437.	0.9	85
51	Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treatment Reviews, 2013, 39, 709-719.	3.4	85
52	Biophysics of Malarial Parasite Exit from Infected Erythrocytes. PLoS ONE, 2011, 6, e20869.	1.1	84
53	Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug Users. Clinical Pharmacokinetics, 1997, 33, 344-400.	1.6	83
54	Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. Journal of Clinical Oncology, 2019, 37, 403-410.	0.8	83

#	Article	IF	CITATIONS
55	A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anti-Cancer Drugs, 2009, 20, 179-184.	0.7	82
56	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer and Prostatic Diseases, 2020, 23, 517-526.	2.0	80
57	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. , 2016, 4, 81.		79
58	Appropriate Use Criteria for ¹⁸ F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. Journal of Nuclear Medicine, 2017, 58, 2026-2037.	2.8	78
59	Prognostic Significance of Pathologic Features in Localized Prostate Cancer Treated With Radical Prostatectomy: Implications for Staging Systems and Predictive Models. Journal of Clinical Oncology, 2001, 19, 3692-3705.	0.8	77
60	Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. European Urology, 2018, 74, 611-620.	0.9	77
61	One-Year Follow-Up of Collaborative Depression Care for Low-Income, Predominantly Hispanic Patients With Cancer. Psychiatric Services, 2011, 62, 162-170.	1.1	76
62	Mediating International Crises. Journal of Conflict Resolution, 2003, 47, 279-301.	1.1	72
63	Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. Journal of Clinical Oncology, 2016, 34, 1500-1509.	0.8	72
64	Radium-223 mechanism of action: implications for use in treatment combinations. Nature Reviews Urology, 2019, 16, 745-756.	1.9	71
65	Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). Clinical Cancer Research, 2017, 23, 7199-7208.	3.2	68
66	Differential growth and shape formation in plant organs. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12359-12364.	3.3	68
67	A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases. Clinical Cancer Research, 2006, 12, 1556-1563.	3.2	63
68	Experience with sorafenib and adverse event management. Critical Reviews in Oncology/Hematology, 2011, 78, 24-32.	2.0	62
69	Microscopic and Gross Extravesical Extension in Pathological Staging of Bladder Cancer. Journal of Urology, 2004, 171, 640-645.	0.2	61
70	Phase I Study of Antisense Oligonucleotide Against Vascular Endothelial Growth Factor: Decrease in Plasma Vascular Endothelial Growth Factor With Potential Clinical Efficacy. Journal of Clinical Oncology, 2006, 24, 1712-1719.	0.8	60
71	Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California. Urologic Oncology: Seminars and Original Investigations. 2013. 31. 1737-1743.	0.8	57
72	Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: A critical analysis of 1,994 patients. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 52.e1-52.e9.	0.8	55

#	Article	IF	CITATIONS
73	Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder. Journal of Urology, 2008, 180, 2384-2388.	0.2	54
74	Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer, 2003, 98, 955-961.	2.0	49
75	Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C study. General Hospital Psychiatry, 2007, 29, 223-231.	1.2	49
76	Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421. Journal of the National Cancer Institute, 2014, 106, dju013.	3.0	49
77	Realâ€world outcomes of sipuleucelâ€T treatment in PROCEED, a prospective registry of men with metastatic castrationâ€resistant prostate cancer. Cancer, 2019, 125, 4172-4180.	2.0	49
78	Power Play: Mediation in Symmetric and Asymmetric International Crises. International Interactions, 2006, 32, 441-470.	0.6	47
79	Targeted α-Particle Therapy of Bone Metastases in Prostate Cancer. Clinical Nuclear Medicine, 2013, 38, 966-971.	0.7	46
80	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046) Urologic Oncology: Seminars and Original Investigations, 2014, 32, 637-644.	0.8	46
81	Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 245-260.	0.8	45
82	Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Targeted Oncology, 2015, 10, 45-53.	1.7	45
83	Multiparametric liquid biopsy analysis in metastatic prostate cancer. JCI Insight, 2019, 4, .	2.3	45
84	IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC) Journal of Clinical Oncology, 2016, 34, 355-355.	0.8	45
85	SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1601-1608.	0.8	44
86	Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. , 2014, 2, 2.		42
87	Up-Regulation of EphB4 in Mesothelioma and Its Biological Significance. Clinical Cancer Research, 2005, 11, 4305-4315.	3.2	41
88	A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Investigational New Drugs, 2013, 31, 1016-1022.	1.2	41
89	Circulating tumor cell telomerase activity as a prognostic marker for overall survival in <scp>SWOG</scp> 0421: A phase III metastatic castration resistant prostate cancer trial. International Journal of Cancer, 2015, 136, 1856-1862.	2.3	41
90	Comparative effectiveness of screening strategies for colorectal cancer. Cancer, 2017, 123, 1516-1527.	2.0	41

#	Article	IF	CITATIONS
91	Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology, Journal of Clinical Oncology, 2013, 31, 131-161.	0.8	40
92	Defective Interhemispheric Integration and Anomalous Language Lateralization in Children at Risk for Schizophrenia. Journal of Nervous and Mental Disease, 1986, 174, 418-427.	0.5	39
93	Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm. Molecular Cancer Therapeutics, 2012, 11, 526-537.	1.9	39
94	Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 6277-6283.	3.2	39
95	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cellâ€free DNA results. Cancer, 2020, 126, 2597-2606.	2.0	39
96	Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma. Clinical Pharmacokinetics, 2009, 48, 199-209.	1.6	37
97	Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer, 2017, 123, 4566-4573.	2.0	37
98	A phase II study of highâ€dose calcitriol combined with mitoxantrone and prednisone for androgenâ€independent prostate cancer. BJU International, 2008, 102, 1601-1606.	1.3	35
99	One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 195-199.	0.7	34
100	Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. Journal of Clinical Oncology, 2018, 36, 1498-1504.	0.8	34
101	Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 61-68.	2.0	34
102	Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Molecular Cancer Therapeutics, 2005, 4, 1105-1113.	1.9	33
103	Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer, 2006, 106, 2624-2629.	2.0	33
104	Cytokine Therapy: A Standard of Care for Metastatic Renal Cell Carcinoma?. Clinical Genitourinary Cancer, 2005, 4, 181-186.	0.9	32
105	Surgery and adjunctive chemotherapy for invasive bladder cancer. Surgical Oncology, 2002, 11, 55-63.	0.8	31
106	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. Journal of Clinical Oncology, 2016, 34, 2478-2483.	0.8	31
107	Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases. Journal of Urology, 2022, 207, 302-313.	0.2	31
108	Is Year of Radical Prostatectomy a Predictor of Outcome in Prostate Cancer?. Journal of Urology, 2004, 171, 692-696.	0.2	30

#	Article	IF	CITATIONS
109	Epidermal Growth Factor Receptor-targeted Therapy in Squamous Cell Carcinoma of the Penis: A Report of 3 Cases. Urology, 2014, 83, 159-166.	0.5	30
110	The mediating effects of effort upon the relationship between head injury severity and cognitive functioning. Brain Injury, 2003, 17, 377-387.	0.6	29
111	Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas, 2011, 69, 296-303.	1.0	29
112	Oral Fenretinide in Biochemically Recurrent Prostate Cancer: A California Cancer Consortium Phase II Trial. Clinical Genitourinary Cancer, 2009, 7, 43-50.	0.9	28
113	Acute Renal Impairment after Immersion and Near-Drowning. Journal of the American Society of Nephrology: JASN, 1999, 10, 382-386.	3.0	28
114	A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2008, 61, 689-694.	1.1	27
115	Crisis managers but not conflict resolvers: Mediating ethnic intrastate conflict in Africa. Conflict Management and Peace Science, 2013, 30, 387-406.	1.0	27
116	Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemotherapy and Pharmacology, 2015, 76, 897-907.	1.1	27
117	Robotic salvage retroperitoneal and pelvic lymph node dissection for â€~nodeâ€only' recurrent prostate cancer: technique and initial series. BJU International, 2017, 120, 401-408.	1.3	27
118	Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clinical Cancer Research, 2018, 24, 4662-4671.	3.2	27
119	Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial. Journal of Thoracic Oncology, 2006, 1, 126-134.	0.5	27
120	Angiogenesis-Targeted Therapies in Prostate Cancer. Clinical Prostate Cancer, 2004, 3, 165-173.	2.1	26
121	The Differential Expression of EphB2 and EphB4 Receptor Kinases in Normal Bladder and in Transitional Cell Carcinoma of the Bladder. PLoS ONE, 2014, 9, e105326.	1.1	26
122	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. Annals of Oncology, 2015, 26, 2392-2398.	0.6	25
123	Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. OncoTargets and Therapy, 2016, Volume 9, 5825-5837.	1.0	25
124	Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with ¹⁸ F-FDG PET/CT. Journal of Nuclear Medicine, 2019, 60, 1524-1530.	2.8	25
125	Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer, 2014, 14, 966.	1.1	24
126	Controlled molecular self-assembly of complex three-dimensional structures in soft materials. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 70-74.	3.3	23

#	Article	IF	CITATIONS
127	Renal-Cell Cancer — Targeting an Immune Checkpoint or Multiple Kinases. New England Journal of Medicine, 2015, 373, 1872-1874.	13.9	22
128	A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 742-749.	0.9	21
129	Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 50-60.	0.4	21
130	Abstract CT001: Neratinib in <i>HER2</i> or <i>HER3</i> mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study. Cancer Research, 2017, 77, CT001-CT001.	0.4	21
131	Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182 Journal of Clinical Oncology, 2019, 37, 4504-4504.	0.8	21
132	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical Cancer Research, 2022, 28, 2050-2060.	3.2	21
133	Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Review of Anticancer Therapy, 2005, 5, 869-874.	1.1	20
134	Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. Clinical Cancer Research, 2021, 27, 1391-1398.	3.2	20
135	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. World Journal of Urology, 2019, 37, 95-105.	1.2	19
136	Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with <i>FGFR3</i> alterations Journal of Clinical Oncology, 2016, 34, 4517-4517.	0.8	19
137	Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC) Journal of Clinical Oncology, 2018, 36, 410-410.	0.8	19
138	Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC) Journal of Clinical Oncology, 2019, 37, 377-377.	0.8	19
139	A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Investigational New Drugs, 2019, 37, 755-762.	1.2	18
140	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma. European Urology, 2020, 78, 916-924.	0.9	18
141	Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). Clinical Cancer Research, 2021, 27, 1967-1973.	3.2	18
142	Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial Journal of Clinical Oncology, 2012, 30, 4-4.	0.8	18
143	Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Review of Anticancer Therapy, 2010, 10, 825-835.	1.1	17
144	Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1 Journal of Clinical Oncology, 2016, 34, LBA4500-LBA4500.	0.8	17

#	ARTICLE	IF	CITATIONS
145	Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC) Journal of Clinical Oncology, 2017, 35, 4501-4501.	0.8	17
146	Review: Targeted therapy in renal cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 183-205.	1.4	16
147	Tivozanib in the treatment of renal cell carcinoma. Biologics: Targets and Therapy, 2013, 7, 139.	3.0	16
148	KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma Journal of Clinical Oncology, 2018, 36, TPS4599-TPS4599.	0.8	16
149	Nonâ€steroidal antiâ€inflammatory drugs. Medical Journal of Australia, 1995, 163, 155-158.	0.8	16
150	Far-Infrared/Submillimeter Astronomical Interferometry with Spaceborne Tether Formations. Astrophysics and Space Science, 2006, 302, 225-239.	0.5	15
151	Pain management, supportive and palliative care in patients with renal cell carcinoma. BJU International, 2007, 99, 1305-1312.	1.3	15
152	Conductive gelatin methacrylate-poly(aniline) hydrogel for cell encapsulation. Biomedical Physics and Engineering Express, 2018, 4, 015005.	0.6	15
153	Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. Theranostics, 2020, 10, 3254-3262.	4.6	15
154	Association of Overall Survival with Glycolytic Activity of Castrate-Resistant Prostate Cancer Metastases. Radiology, 2015, 274, 624-625.	3.6	14
155	<i>AXIN2</i> expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate, 2016, 76, 597-608.	1.2	14
156	Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Investigational New Drugs, 2020, 38, 1807-1814.	1.2	14
157	Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. Clinical Genitourinary Cancer, 2020, 18, 351-360.e3.	0.9	14
158	Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts) Journal of Clinical Oncology, 2016, 34, 4513-4513.	0.8	14
159	Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). Journal of Clinical Oncology, 2022, 40, 3301-3309.	0.8	14
160	Oblimersen and α-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. Journal of Cancer Research and Clinical Oncology, 2007, 133, 705-711.	1.2	13
161	Cabazitaxel in prostate cancer: stretching a string. Lancet, The, 2010, 376, 1119-1120.	6.3	13
162	Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts. Cancers, 2019, 11, 577.	1.7	13

#	Article	IF	CITATIONS
163	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clinical Cancer Research, 2019, 25, 7381-7387.	3.2	13
164	FDG PET/CT Demonstration of Pancreatic Metastasis From Prostate Cancer. Clinical Nuclear Medicine, 2011, 36, 961-962.	0.7	12
165	Immune Response to Sipuleucel-T in Prostate Cancer. Cancers, 2012, 4, 420-441.	1.7	12
166	Small Cell Bladder Cancer: Biology and Management. Seminars in Oncology, 2012, 39, 615-618.	0.8	12
167	What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 6S-12S.	2.8	12
168	Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. Investigational New Drugs, 2021, 39, 812-820.	1.2	12
169	Molecular prognostic factors in bladder cancer. BJU International, 2005, 95, 739-742.	1.3	11
170	Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU International, 2008, 102, 1086-1091.	1.3	11
171	Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World Journal of Urology, 2009, 27, 39-44.	1.2	11
172	Using Molecular Markers to Help Predict Who Will Fail after Radical Prostatectomy. Prostate Cancer, 2011, 2011, 1-15.	0.4	11
173	Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 74, 1227-1234.	1.1	11
174	Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients. Clinical Genitourinary Cancer, 2018, 16, 90-98.e1.	0.9	11
175	Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clinical Genitourinary Cancer, 2019, 17, 241-247.e1.	0.9	11
176	Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 1-11.	0.8	11
177	Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. JCO Clinical Cancer Informatics, 2020, 4, 839-853.	1.0	11
178	Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. Journal of Thoracic Oncology, 2006, 1, 126-34.	0.5	11
179	Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). Journal of Patient-Reported Outcomes, 2018, 2, 27.	0.9	10
180	p53 nuclear accumulation as an early indicator of lethal prostate cancer. British Journal of Cancer, 2019, 121, 578-583.	2.9	10

#	Article	IF	CITATIONS
181	Protocol for a multi-centre, definitive randomised controlled trial of the effectiveness of Individual Placement and Support for employment support among people with alcohol and drug dependence. Trials, 2020, 21, 167.	0.7	10
182	Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients Journal of Clinical Oncology, 2019, 37, 2572-2572.	0.8	10
183	The Current and Future Application of Adjuvant Systemic Chemotherapy in Patients with Bladder Cancer Following Cystectomy. Urologic Clinics of North America, 2005, 32, 217-230.	0.8	9
184	A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma. International Journal of Clinical Oncology, 2011, 16, 494-9.	1.0	9
185	Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Review of Clinical Pharmacology, 2014, 7, 67-73.	1.3	9
186	Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clinical Genitourinary Cancer, 2018, 16, e11-e21.	0.9	9
187	Radionuclide Hepatobiliary Scanning in Patients with AIDS-Related Sclerosing Cholangitis. Clinical Nuclear Medicine, 1993, 18, 417-422.	0.7	8
188	Characteristics of Early-Winter Caribou, Rangifer tarandus caribou , Feeding Sites in the Southern Purcell Mountains, British Columbia. Canadian Field-Naturalist, 2003, 117, 352.	0.0	8
189	First light adaptive optics systems and components for the Thirty Meter Telescope. Proceedings of SPIE, 2010, , .	0.8	8
190	Smoke-Free Multi-unit Housing Policies Show Promise in Reducing Secondhand Smoke Exposure Among Racially and Ethnically Diverse, Low-Income Seniors. Journal of Immigrant and Minority Health, 2017, 19, 1281-1289.	0.8	8
191	Training early childcare providers in evidence-based nutrition strategies can help improve nutrition policies and practices of early childcare centres serving racially and ethnically diverse children from low-income families. Public Health Nutrition, 2018, 21, 1212-1221.	1.1	8
192	Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). Journal of Clinical Oncology, 2019, 37, 2682-2688.	0.8	8
193	Habitat segregation and population structure of Caribbean sea anemones and associated crustaceans on coral reefs at Akumal Bay, Mexico. Bulletin of Marine Science, 2017, 93, 1025-1047.	0.4	8
194	Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis. International Journal of Molecular Sciences, 2022, 23, 2571.	1.8	8
195	An Audit of Oestrogen Implant Hormone Replacement Therapy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1998, 38, 455-460.	0.4	7
196	Phase I Clinical Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Patients With Advanced Solid Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 27-31.	0.6	7
197	Efficacy of Oxaliplatin Plus Pemetrexed in Chemotherapy Pretreated Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2013, 11, 416-422.	0.9	7
198	Cancer transcriptomic profiling from rapidly enriched circulating tumor cells. International Journal of Cancer, 2020, 146, 2845-2854.	2.3	7

#	Article	IF	CITATIONS
199	Overall survival and immune responses with sipuleucel-T and enzalutamide: STRIDE study Journal of Clinical Oncology, 2018, 36, 246-246.	0.8	7
200	Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results Journal of Clinical Oncology, 2019, 37, 4510-4510.	0.8	7
201	Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. Clinical Genitourinary Cancer, 2016, 14, 450-456.e1.	0.9	6
202	Sipuleucel-T product characterization across different disease states of prostate cancer Journal of Clinical Oncology, 2012, 30, 42-42.	0.8	6
203	Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT) Journal of Clinical Oncology, 2013, 31, 336-336.	0.8	6
204	The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials Journal of Clinical Oncology, 2014, 32, 5002-5002.	0.8	6
205	Eribulin in advanced urothelial cancer (AUC) patients (pts): A California Cancer Consortium trial—NCI/CTEP 7435 Journal of Clinical Oncology, 2015, 33, 4504-4504.	0.8	6
206	Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045 Journal of Clinical Oncology, 2017, 35, 4530-4530.	0.8	6
207	Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis Journal of Clinical Oncology, 2019, 37, 5035-5035.	0.8	6
208	Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clinical Advances in Hematology and Oncology, 2017, 15, 543-551.	0.3	6
209	Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 12.e13-12.e22.	0.8	6
210	Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Future Oncology, 2016, 12, 2689-2699.	1.1	5
211	Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clinical Genitourinary Cancer, 2017, 15, 635-641.	0.9	5
212	Low-dimensional dynamical characterization of human performance of cancer patients using motion data. Clinical Biomechanics, 2018, 56, 61-69.	0.5	5
213	NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer Journal of Clinical Oncology, 2014, 32, 296-296.	0.8	5
214	Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC) Journal of Clinical Oncology, 2016, 34, 11516-11516.	0.8	5
215	Single arm phase II study of docetaxel and lapatinib in metastatic urothelial cancer: USC trial 4B-10-4 Journal of Clinical Oncology, 2016, 34, 424-424.	0.8	5
216	Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564 Journal of Clinical Oncology, 2018, 36, TPS712-TPS712.	0.8	5

#	Article	IF	CITATIONS
217	Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 35-42.	0.9	5
218	Show us a sign: the search for "game changing―prostate cancer biomarkers. Lancet Oncology, The, 2011, 12, 204-206.	5.1	4
219	Blood cells and their use in active immunotherapy of prostate cancer. Human Vaccines and Immunotherapeutics, 2012, 8, 528-533.	1.4	4
220	Warfarin Ridge. Journal of the American College of Cardiology, 2013, 62, 1213.	1.2	4
221	Rapid changes in circulating tumor cells following anti-angiogenic therapy. Convergent Science Physical Oncology, 2015, 1, 015002.	2.6	4
222	Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital?. Clinical Genitourinary Cancer, 2018, 16, e719-e727.	0.9	4
223	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer, 2019, 125, 3853-3863.	2.0	4
224	Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 486-493.	2.0	4
225	HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2 Journal of Clinical Oncology, 2013, 31, 292-292.	0.8	4
226	Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence Journal of Clinical Oncology, 2014, 32, 4541-4541.	0.8	4
227	A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2014, 32, e16071-e16071.	0.8	4
228	Multicenter sequential phase II study of flavopiridol plus oxaliplatin (Alvocidib) with or without 5-FU and leucovorin (LV) for patients (pts) with refractory germ cell tumors (GCT) including late relapse (LR) Journal of Clinical Oncology, 2014, 32, 364-364.	0.8	4
229	Survival outcomes for African-American (AA) vs matched Caucasian (CAU) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (sip-T) Journal of Clinical Oncology, 2017, 35, 192-192.	0.8	4
230	Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study Journal of Clinical Oncology, 2018, 36, 431-431.	0.8	4
231	P53 as a predictor of clinical outcome in localized prostate cancer Journal of Clinical Oncology, 2018, 36, 57-57.	0.8	4
232	A phase II study of ribociclib in men with unresectable, incurable teratoma with recent progression Journal of Clinical Oncology, 2019, 37, 517-517.	0.8	4
233	Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. Current Oncology Reports, 2022, 24, 1287-1298.	1.8	4
234	Dissecting the rugby tackle: do shoulder pads contribute to cervical spine injuries?. Medical Journal of Australia, 1998, 169, 501-502.	0.8	3

#	Article	IF	CITATIONS
235	"The Wizard of Oz:―A Depiction of TBI-Related Neurobehavioral Syndromes. Academic Psychiatry, 2012, 36, 340.	0.4	3
236	FINITE DOMINATION AND NOVIKOV RINGS. ITERATIVE APPROACH. Glasgow Mathematical Journal, 2013, 55, 145-160.	0.2	3
237	Finite domination and Novikov rings: Laurent polynomial rings in two variables. Journal of Algebra and Its Applications, 2015, 14, 1550055.	0.3	3
238	Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 459.e15-459.e24.	0.8	3
239	Mining Human Mobility to Quantify Performance Status. , 2017, , .		3
240	Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers. Cancer Research, 2018, 78, 5560-5560.	0.4	3
241	Examining the management of muscle-invasive bladder cancer (MIBC) by medical oncologists (MO) Journal of Clinical Oncology, 2012, 30, 298-298.	0.8	3
242	Multi-parametric liquid biopsy analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and cell-free RNA (cfRNA) in metastatic castrate resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2018, 36, 274-274.	0.8	3
243	Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. Clinical Advances in Hematology and Oncology, 2017, 15, 466-477.	0.3	3
244	Bladder cancer: from a therapeutic wilderness to so many options; aÂguide to practice in a changing landscape. Annals of Oncology, 2022, 33, 242-243.	0.6	3
245	Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis. Investigational New Drugs, 2006, 24, 79-83.	1.2	2
246	Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 69-77.	1.4	2
247	953 SIPULEUCEL-T IN AFRICAN AMERICANS: A SUBGROUP ANALYSIS OF THREE PHASE 3 TRIALS OF SIPULEUCEL-T IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER. Journal of Urology, 2012, 187, .	0.2	2
248	Skate park injury: A new mechanism of sternoclavicular joint dislocation. EMA - Emergency Medicine Australasia, 2014, 26, 316-317.	0.5	2
249	Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study. Cancer Chemotherapy and Pharmacology, 2017, 79, 339-351.	1.1	2
250	Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 485-489.	0.7	2
251	Immune response from STRIDE, a randomized, phase 2, open label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2015, 33, 5040-5040.	0.8	2
252	Safety and efficacy of everolimus (E), bevacizumab (B), and docetaxel (D) for castration resistant prostate cancer (CRPC) Journal of Clinical Oncology, 2015, 33, 5066-5066.	0.8	2

#	Article	lF	CITATIONS
253	A phase I/Ib, open-label, dose-finding study to evaluate safety, pharmacodynamics, and efficacy of pembrolizumab (MK-3475) in combination with vorinostat in patients with advanced renal or urothelial cell carcinoma Journal of Clinical Oncology, 2016, 34, TPS4581-TPS4581.	0.8	2
254	Adjuvant axitinib dose modification in renal cell carcinoma (RCC): Analysis of the ATLAS study Journal of Clinical Oncology, 2019, 37, 4573-4573.	0.8	2
255	Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2019, 37, 186-186.	0.8	2
256	Towards the cloning of the calf prochymosin gene. Biochemical Society Transactions, 1984, 12, 487-488.	1.6	1
257	Urethral Cancer. , 2006, , 27-37.		1
258	Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: â€~plus or minus' may be a minus. Annals of Oncology, 2013, 24, 270-272.	0.6	1
259	Chromoplexy and hypoxic microenvironment drives prostate cancer. Lancet Oncology, The, 2014, 15, 1419-1421.	5.1	1
260	Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Review of Anticancer Therapy, 2014, 14, 51-61.	1.1	1
261	Oscillometric blood pressure. Blood Pressure Monitoring, 2014, 19, 255.	0.4	1
262	Durable Complete Remission From Castration-Resistant Prostate Cancer With Sipuleucel-T After Estrogen Withdrawal. Clinical Genitourinary Cancer, 2014, 12, e55-e58.	0.9	1
263	Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 341-342.	0.8	1
264	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectrum, 2020, 4, pkaa003.	1.4	1
265	Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature. Clinical Genitourinary Cancer, 2020, 18, e473-e477.	0.9	1
266	Abstract 2718: Fasting and cancer treatment: A case series. , 2010, , .		1
267	Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study. , 2019, , .		1
268	HPV status in relation to clinicopathologic variables in patients with penile cancer at Los Angeles County-USC Medical Center Journal of Clinical Oncology, 2012, 30, 329-329.	0.8	1
269	Changes in circulating tumor cells (CTC) and markers of inflammation after sipuleucel-T treatment Journal of Clinical Oncology, 2013, 31, 40-40.	0.8	1
270	International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI-906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC) Journal of Clinical Oncology, 2014, 32, 4507-4507.	0.8	1

#	Article	IF	CITATIONS
271	SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer Journal of Clinical Oncology, 2014, 32, 5006-5006.	0.8	1
272	Abiraterone plus prednisone alone or with dasatinib in chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2014, 32, TPS5108-TPS5108.	0.8	1
273	Randomized phase 2 study of trebananib (AMG 386) with or without continued anti-vascular endothelial growth factor (VEGF) therapy in patients (pts) with renal cell carcinoma (RCC) who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib Journal of Clinical Oncology, 2016, 34, e16121-e16121.	0.8	1
274	Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose Interleukin 2 in renal cell carcinoma patients (CTEP#7870) Journal of Clinical Oncology, 2016, 34, 500-500.	0.8	1
275	Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC) Journal of Clinical Oncology, 2017, 35, 143-143.	0.8	1
276	Impact of resistance exercise on metabolic syndrome (MetS) parameters in men receiving androgen deprivation therapy (ADT) for prostate cancer Journal of Clinical Oncology, 2017, 35, 223-223.	0.8	1
277	THE INCIDENCE ALGEBRA OF POSETS AND ACYCLIC CATEGORIES. Kyushu Journal of Mathematics, 2013, 67, 117-127.	0.2	1
278	ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC) Journal of Clinical Oncology, 2014, 32, TPS4595-TPS4595.	0.8	1
279	Sipuleucel-T (sip-T)–induced proliferative CD8+ T-cell responses to immunizing and secondary antigens Journal of Clinical Oncology, 2016, 34, 165-165.	0.8	1
280	Comparative effectiveness of initiating colorectal cancer (CRC) screening (Scr) at age 45 Journal of Clinical Oncology, 2017, 35, 531-531.	0.8	1
281	Randomized phase II trial of abiraterone +/- dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2017, 35, 167-167.	0.8	1
282	Impact of timing of administration of bone supportive therapy on pain palliation from radium-223 Journal of Clinical Oncology, 2017, 35, 5023-5023.	0.8	1
283	High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry Journal of Clinical Oncology, 2018, 36, 624-624.	0.8	1
284	Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT) Journal of Clinical Oncology, 2019, 37, 4563-4563.	0.8	1
285	The future in advanced prostate cancer: take your partners or is the last dance for me?. Reviews in Urology, 2004, 6 Suppl 10, S29-44.	0.9	1
286	A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 415-422.	0.9	1
287	Tinea of the skin, hair and nails. Medical Journal of Australia, 1996, 165, 350-351.	0.8	Ο
288	Creative approaches to staff development: global education in ITE in The Gambia. Education 3-13, 2007, 35, 117-131.	0.6	0

#	Article	lF	CITATIONS
289	Perioperative chemotherapy for urothelial cancer. Cancer, 2009, 115, 5139-5142.	2.0	0
290	RAPIDLY ALTERNATING, DOSE-DENSE CHEMOTHERAPY AND RETROPERITONEAL LYMPH NODE DISSECTION (RPLND): OUTCOMES IN PATIENTS WITH HIGH-RISK NON-SEMINOMATOUS GERM CELL TUMOR. Journal of Urology, 2009, 181, 198-198.	0.2	0
291	1983 FACTORS INFLUENCING POST-RECURRENCE SURVIVAL IN BLADDER CANCER PATIENTS FOLLOWING RADICAL CYSTECTOMY. Journal of Urology, 2011, 185, .	0.2	0
292	1589 INFLUENCE OF SMOKING HISTORY ON BLADDER CANCER PATIENT OUTCOME FOLLOWING RADICAL CYSTECTOMY. Journal of Urology, 2011, 185, .	0.2	0
293	MP41-09 AXIN2 PREDICTS PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.2	0
294	MP61-15 IMPACT OF GENDER ON POST-CYSTECTOMY BLADDER CANCER OUTCOMES: DIFFERENCES IN OBSERVATIONS BETWEEN MATCHED AND UNMATCHED CASE-CONTROL APPROACHES. Journal of Urology, 2014, 191, .	0.2	0
295	PD31-10 OUTCOMES FOLLOWING POST-CYSTECTOMY RECURRENCE OF BLADDER CANCER BASED ON METASTATIC SITE. Journal of Urology, 2015, 193, .	0.2	0
296	Trauma care and education. Clinical Teacher, 2015, 12, 291-291.	0.4	0
297	PD27-12 PRIMARY ANALYSIS OF IMVIGOR 210: ATEZOLIZUMAB IN PLATINUM-TREATED ADVANCED UROTHELIAL CARCINOMA. Journal of Urology, 2016, 195, .	0.2	0
298	MP06-05 PRECYSTECTOMY EPITHELIAL TUMOR MARKER RESPONSE TO NEOADJUVANT CHEMOTHERAPY AND ITS EFFECT ON ONCOLOGICAL OUTCOMES IN UROTHELIAL BLADDER CANCER. Journal of Urology, 2016, 195, .	0.2	0
299	Finite domination and Novikov rings. Laurent polynomial rings in several variables. Journal of Pure and Applied Algebra, 2016, 220, 2648-2682.	0.3	0
300	PD62-11 PREDICTIVE ROLE OF EPITHELIAL TUMOR MARKER LEVEL ELEVATION AT FOLLOW-UP FOR TUMOR RECURRENCE AND ONCOLOGICAL OUTCOMES IN UROTHELIAL BLADDER CANCER. Journal of Urology, 2017, 197, .	0.2	0
301	Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. Future Oncology, 2018, 14, 527-536.	1.1	0
302	EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy. Pathology Research and Practice, 2020, 216, 152967.	1.0	0
303	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. Cancer, 2020, 126, 2935-2937.	2.0	0
304	Chapter 7 Systemic treatment: targeted therapies. , 2010, , .		0
305	Emerging Agents in Renal Cell Carcinoma. , 2012, , 285-301.		0
306	A combination herbal supplement for biochemically recurrent prostate cancer Journal of Clinical Oncology, 2012, 30, 24-24.	0.8	0

#	Article	IF	CITATIONS
307	Neoadjuvant chemotherapy for muscle-invasive bladder cancer at the University of Southern California Journal of Clinical Oncology, 2012, 30, 301-301.	0.8	0
308	A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer Journal of Clinical Oncology, 2012, 30, 60-60.	0.8	0
309	The University of Southern California penile cancer experience: Clinicopathologic characteristics of patients from 1991 to 2011 Journal of Clinical Oncology, 2012, 30, 342-342.	0.8	0
310	Abstract LB-227: Targeted next-generation sequencing (NGS) of circulating tumor cells (CTCs) and matched primary tumors , 2013, , .		0
311	Identification of biologic and inflammatory markers for predicting clinical responses to sipuleucel-T in CRPC Journal of Clinical Oncology, 2014, 32, 134-134.	0.8	0
312	Clinical and biologic factors for immune response to sipuleucel-T (SipT) for metastatic castrate-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2014, 32, 219-219.	0.8	0
313	Prostatectomy at high- versus low-volume centers: A decision analysis Journal of Clinical Oncology, 2014, 32, 175-175.	0.8	0
314	AXIN2 and prostate cancer recurrence after radical prostatectomy Journal of Clinical Oncology, 2014, 32, 145-145.	0.8	0
315	SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (HSPC) (NCT01809691) Journal of Clinical Oncology, 2014, 32, TPS5102-TPS5102.	0.8	0
316	Emerging Agents in Renal Cell Carcinoma. , 2015, , 385-402.		0
317	Dynamic changes in biomarkers for immune response to sipuleucel-t (SipT) for metastatic castrate-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2015, 33, 181-181.	0.8	0
318	Effect of AXIN2 expression on prostate cancer recurrence and an invasive, tumorigenic phenotype Journal of Clinical Oncology, 2015, 33, 29-29.	0.8	0
319	Bevacizumab (Bev) alone or in combination with TRC105 for metastatic renal cell cancer (mRCC): A California Cancer Consortium clinical trial Journal of Clinical Oncology, 2015, 33, 4542-4542.	0.8	0
320	Colonoscopy versus less invasive approaches for colorectal cancer (CRC) screening (Scr): A strategic perspective Journal of Clinical Oncology, 2015, 33, 6523-6523.	0.8	0
321	Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with hepatic impairment (HI) Journal of Clinical Oncology, 2015, 33, 2538-2538.	0.8	0
322	AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth Journal of Clinical Oncology, 2015, 33, e16092-e16092.	0.8	0
323	Abstract 1587: Targeted sequencing of prostate cancer circulating tumor cells in comparison with matched cell free DNA and prostate tumors. , 2015, , .		0
324	Randomized phase I/II trial of two schedules of bortezomib and bevacizumab (BBmibmab) in metastatic renal cell cancer: USC trial 4K-05-1 Journal of Clinical Oncology, 2016, 34, 574-574.	0.8	0

#	Article	IF	CITATIONS
325	Angiogenic markers during bevacizumab-based treatment in metastatic renal cell carcinoma (RCC) Journal of Clinical Oncology, 2016, 34, 522-522.	0.8	0
326	Baseline GFR and cisplatin-induced renal toxicity in urothelial cancer patients Journal of Clinical Oncology, 2016, 34, 380-380.	0.8	0
327	The TRUMPET registry: Assessing clinical outcomes and quality of life in patients with castration-resistant prostate cancer and their caregivers Journal of Clinical Oncology, 2016, 34, 241-241.	0.8	Ο
328	Sipuleucel-T (sip-T)–induced lytic CD8+ T cell responses to target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC) Journal of Clinical Oncology, 2016, 34, e23116-e23116.	0.8	0
329	Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/enzalutamide (Enz) sensitive and resistant metastatic castrate-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2016, 34, 5077-5077.	0.8	0
330	FOBT compared to FIT in reducing colorectal cancer (CRC) incidence Journal of Clinical Oncology, 2016, 34, e18119-e18119.	0.8	0
331	The opportunity cost (OC) of low adherence with screening (scr) recommendations for colorectal cancer (CRC) Journal of Clinical Oncology, 2016, 34, 1553-1553.	0.8	0
332	Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421 Journal of Clinical Oncology, 2016, 34, 5079-5079.	0.8	0
333	Adjuvant chemotherapy for bladder cancer: A detailed characterization of factors precluding utilization Journal of Clinical Oncology, 2016, 34, e16001-e16001.	0.8	0
334	Targeted next generation sequencing (NGS) of matched primary tumor, metastasis, circulating tumor cells (CTCs), and cell-free DNA (cfDNA) in a patient with advanced prostate cancer (PC) Journal of Clinical Oncology, 2016, 34, e23057-e23057.	0.8	0
335	The opportunity cost (OC) of performing radical prostatectomy (RP) by low volume (LV) providers (Prov) Journal of Clinical Oncology, 2016, 34, 6509-6509.	0.8	0
336	Outcomes in neuroendocrine bladder cancer treated with radical cystectomy Journal of Clinical Oncology, 2016, 34, e16004-e16004.	0.8	0
337	Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose interleukin 2 in metastatic renal cell carcinoma patients (CTEP#7870) Journal of Clinical Oncology, 2016, 34, 4560-4560.	0.8	0
338	Comparative effectiveness of CT colonography (CT-C) as a screening (Scr) tool for colorectal cancer (CRC) Journal of Clinical Oncology, 2016, 34, e13049-e13049.	0.8	0
339	Abstract 3160: Circulating tumor cell enrichment and dielectric manipulation for ultra-pure cell recovery in advanced bladder cancer. , 2016, , .		0
340	Abstract CT015: Results from a phase I/II study with the HDAC inhibitor entinostat in combination with high-dose interleukin-2 in renal cell carcinoma patients (CTEP#7870). , 2016, , .		0
341	Eligibility criteria and endpoints in metastatic renal cell carcinoma trials Journal of Clinical Oncology, 2017, 35, 465-465.	0.8	0
342	Cytokine profile of sipuleucel-T (sip-T) in differentiating reactivation of latent immunity from de novo immune responses Journal of Clinical Oncology, 2017, 35, 163-163.	0.8	0

#	Article	IF	CITATIONS
343	P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs) Journal of Clinical Oncology, 2017, 35, TPS4592-TPS4592.	0.8	0
344	Adjuvant androgen deprivation (AD) +/- mitoxantrone + prednisone (MP) in patients with high-risk prostate cancer (PC) post radical prostatectomy (RP): Phase III intergroup trial S9921 Journal of Clinical Oncology, 2017, 35, 5019-5019.	0.8	0
345	Sipuleucel-T (sip-T) to induce cytolytic T lymphocyte (CTL) activity against target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC) Journal of Clinical Oncology, 2017, 35, 5046-5046.	0.8	0
346	Abstract 1717: Orthogonal identification of circulating tumor cells (CTCs) using single cell low pass whole-genome sequencing (WGS) and copy-number alteration (CNA) analysis. , 2017, , .		0
347	CT-based texture characterization of lymphadenopathy in urothelial carcinoma: Prediction of treatment response Journal of Clinical Oncology, 2018, 36, 514-514.	0.8	0
348	Novel method for rapid enrichment of high purity circulating tumor cells (CTCs) for prostate cancer (PCa) gene expression profiling Journal of Clinical Oncology, 2018, 36, 271-271.	0.8	0
349	Immune-related adverse events (irAE) in GU cancer patients receiving immune checkpoint inhibitors Journal of Clinical Oncology, 2018, 36, 422-422.	0.8	0
350	P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs) Journal of Clinical Oncology, 2018, 36, TPS574-TPS574.	0.8	0
351	Relationship between sipuleucel-T (sip-T) cytolytic T lymphocyte (CTL) activity and overall survival (OS) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2018, 36, 5027-5027.	0.8	0
352	Interpreting survival outcomes for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (SIP-T) with number needed to treat to benefit (NNTB) Journal of Clinical Oncology, 2019, 37, 222-222.	0.8	0
353	EphB4-EphrinB2 receptor-ligand pair as a novel target in prostate cancer (PC) Journal of Clinical Oncology, 2019, 37, 275-275.	0.8	0
354	Association of next generation sequencing characteristics of MIBC specimens with clinical outcomes: The USC experience Journal of Clinical Oncology, 2019, 37, 397-397.	0.8	0
355	Simple and rapid enrichment of circulating tumor cells (CTCs) for RNAseq in metastatic castrate resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2019, 37, e16587-e16587.	0.8	0
356	PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2019, 37, 5021-5021.	0.8	0
357	Abstract 3139: EphB4-EphrinB2 receptor-ligand are downstream effectors and novel targets of PTEN deficient prostate cancer. , 2019, , .		0
358	Editorial Comment. Journal of Urology, 2020, 203, 336-337.	0.2	0
359	Reply by Authors. Journal of Urology, 2022, 207, 313-313.	0.2	0
360	Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials Journal of Clinical Oncology, 2022, 40, 516-516.	0.8	0

#	Article	IF	CITATIONS
361	Abstract 3736: SETD2 aberrancy enhanced the synergetic anti-tumor effects of DNA hypomethylating agents and PARP inhibitors in aggressive clear cell renal cell carcinoma. Cancer Research, 2022, 82, 3736-3736.	0.4	0